The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 11, Issue 3, 1996, Pages 247-257

  Klausner, Jeffrey D ^a   Makonkawkeyoon, Sanit ^b   Akarasewi, Pasakorn ^c   Nakata, Koh ^a   Kasinrerk, Watchara ^b   Corral, Laura ^d   Dewar, Robin L ^e   Clifford Lane, H ^e   Freedman, Victoria H ^f   Kaplan, Gilla ^a,f  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b Faculty of Medicine Chiang Mai University   (Thailand)

^c Chiang Mai Anti TB Association   (Thailand)

^d CELGENE CORPORATION   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Human immunodeficiency syndrome type 1; Thalidomide; Tuberculosis; Tumor necrosis factor alpha (TNF ); Wasting

Indexed keywords

PLACEBO; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIMICROBIAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEVER; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUSCLE WEAKNESS; MYCOBACTERIUM TUBERCULOSIS; PATHOGENESIS; PRIORITY JOURNAL; TUBERCULOSIS; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0000387375     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199603010-00005     Document Type: Article

References (33)

1. Lahdevirta J, Maury CP, Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:289-91.
2. Hober D, Haque A, Wattre P, Beaucaire G, Mouton Y, Capron A. Production of tumour necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1) in patients with AIDS: Enhanced level of TNF-α is related to a higher cytotoxic activity. Clin Exp Immunol 1989;78:329-33.
3. Kobayashi S, Hamamoto Y, Kobayashi N, Yamamoto N. Serum level of TNF-α in HIV-infected individuals. AIDS 1990;4:169-70.
4. Godfried MH, van der Poll T, Weverling GJ, et al. Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994;169:739-45.
5. Matsuyama T, Kobayashi N, Yamamoto N. Cytokines and HIV infection: Is AIDS a tumor necrosis factor disease? AIDS 1991;5:1405-17.
6. Grunfeld C, Kotler DP. Pathophysiology of the AIDS wasting syndrome. AIDS Clin Rev 1992:191-224.
7. Aukrust P, Liabakk N-B, Muller F, Lien E, Espevik T, Freland SS. Serum levels of tumor necrosis factor-α (TNF-α) and soluble TNF receptors in human immunodeficiency virus type 1 infection: correlations to clinical, immunologic and virologic parameters. J Infect Dis 1994;169:420-4.
8. Clouse KA, Powell D, Washington I, et al. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol 1989;142:431-8.
9. Folks TM, et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA 1989;86:2365-8.
10. Michihiko S, Yamamoto N, Shinozaki F, et al. Augmentation of in-vitro HIV replication in peripheral blood mononuclear cells of AIDS and ARC patients by tumour necrosis factor. Lancet 1989;1:1206-7.
11. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci USA 1989;86:5974-8.
12. Barnes PF, Fong SJ, Brennan PJ, et al. Local production of tumor necrosis factor and IFN-γ in tuberculous pleuritis. J Immunol 1990;145:149-54.
13. Tramontana JM, Utaipat U, Molloy A, et al. Thalidomide treatment reduces TNF-α production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:384-97.
14. Valone SE, Rich E, Wallis RS, Ellner JJ. Expression of tumor necrosis factor in vitro by human mononuclear phagocytes stimulated with whole Mycobacterium bovis BCG and mycobacterial antigens. Infect Immunol 1988;56:3313-5.
15. Moreno C, Javerne J, Mehlert A, et al. Lipoarabinomannan from Mycobacterium tuberculosis induces the production of tumour necrosis factor from human and murine macrophages. Clin Exp Immunol 1989;76:240-5.
16. Wallis RS, Amir-Tahmasseb M, Ellner JJ. Induction of interleukin 1 and tumor necrosis factor by mycobacterial proteins: the monocyte Western blot. Proc Natl Acad Sci USA 1990;87:3348-52.
17. Zhang Y, Doerfler M, Lee TC, Guillemin B, Rom WN. Mechanisms of stimulation of Interleukin-1 beta and tumor necrosis factor-alpha by Mycobacterium tuberculosis components. J Clin Invest 1993;91:2076-83.
18. Wallis RS, Vjecha M, Amir-Tahmasseb M, et al. Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated beta 2-microglobulin in HIV-1-associated tuberculosis. J Infect Dis 1993;167:43-8.
19. Lederman MM, Georges DL, Kusner DJ, Mudido P, Giam CZ, Toossi Z. Mycobacterium tuberculosis and its purified protein derivative activate expression of the human immunodeficiency virus. J AIDS 1994;7:727-33.
20. Zhang Y, Nakata K, Weiden M, Rom WN. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat. J Clin Invest 1995;95:2324-31.
21. Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G. Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992;175:1729-37.
22. Makonkawkeyoon S, Limson-Pobre RN, Moreira AL, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90:5974-8.
23. Dewar RL, Highbarger HC, Sarmiento MD, et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis 1994;170:1172-9.
24. Holodniy M, Mole L, Yen-Lieberman B, et al. Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in Vacutainer CPT, Vacutainer PPT, and standard Vacutainer tubes. J Clin Microbiol 1995;33:1562-6.
25. Kaplan G, Moreira AL. TNF-α regulation of HIV-1: biology and therapy. Res Immunol 1994;145:685-90.
26. Beutler B, Cerami A. The common mediator of shock, cachexia and tumor necrosis. Adv Immunol 1988;42:213-31.
27. Tracey KJ, Cerami A. Tumor necrosis factor in the malnutrition (cachexia) of infection and cancer. Am J Trop Med Hyg 1992;47:suppl. 1, Pt 2:2-7.
28. Rouzer CA, Cerami A. Hypertriglyceridemia associated with Trypanosoma brucei infection in rabbits: role of defective triglyceride removal. Mol Biochem Parasitol 1980;2:31-8.
29. Poli G, Kinter A, Justement JS, et al. Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 1990;87:782-5.
30. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1995;173:699-703.
31. Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993;168:408-14.
32. Williams I, Weller IVD, Malni A, Anderson J, Waters MF. Thalidomide hypersensitivity in AIDS. Lancet 1991;337:436-7.
33. Gunzler V. Thalidomide in human immunodeficiency virus (HIV) patients: a review of safety considerations. Drug Safety 1992;7:116-34.